Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel tetramerization domain-containing protein 2 (KCTD2) is a soluble, non-channel protein that functions primarily as an adaptor for Cullin3-dependent E3 ubiquitin ligase complexes, facilitating the ubiquitination and degradation of specific substrates including the oncogene c-Myc. The protein has a conserved BTB/POZ domain that mediates oligomerization and protein interactions. KCTD2 is implicated in transcriptional repression, cytoskeleton regulation, and modulation of stem cell features in tumors. It is evolutionarily related to the tetramerization domains of voltage-gated potassium channels, despite not forming a channel itself. Its role in the ubiquitination pathway has been highlighted in cancers, especially malignant gliomas, where its loss leads to increased c-Myc levels, promoting tumor growth and stemness[1][2][5].
Adaptor-mediated ubiquitination and degradation of target proteins such as c-Myc (a key stem cell factor and oncogene); Suppression of stem cell-like features and aerobic glycolysis in glioma cells via c-Myc regulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium channel tetramerization domain-containing protein 2 (KCTD2).